ICON plc (ADR) (ICLR)

Good fundamentals, steady growth in revenue and profit. It seems like they recently made some acquisitions and this is the reason it dropped down from $40, which I think it should return to relatively soon. Very little debt!

I love companies that serve other companies. Regardless of the success or failure of a drug trial, this company makes money.

Blanket pick on the CRO market under the assumption that it will return to growth in 2010. This just seems like the right time to make this call (we'll see).

TMFHelical

A history of growth. Strong financials. Should not be hurt too badly in a recession. Top management is invested.

I sold this stock today. I bought in at $15 last month and I am taking my 36% profit. I have it written down to get out before July as I feel the stock will have some poorer earnings reports. However, long term this stock is a sure fire winner, just not the next month. I'll re-evaluate it in August.

Low relative PE, good star ranking, PEG & 09 PE still below normal - bottom fishing 4/27 picks.

A good buy even at $23 according to the high scores on the Scorecard. Near 52 week low. Healthcare industry has high growth potential. Followed another 99% member to this pick.

As a company that helps drug developers test and validate new medicines, ICLR's business is mostly independent of the success or failure of those new drugs. In other words, they get paid whether or not the drug they're testing works. While one could argue that the stock price wouldn't benefit from a blockbuster drug discovery, it's also insulated from the kind of sudden drop that can follow disappointing news about clinical trials.

As long as healthcare costs are a national issue, and as long as Icon keeps doing what they've been doing, I see few reasons to doubt a quick recovery for the stock price and a promising future in the 2-10 year window. Now that the stock price is off it's 52-week low and inching up, I'm a buyer.

They claim to have been hurt by a strong dollar, great news since Comrade Obama loves inflation and a weak dollar.

ICLR is a very solid company that I consider to be on the upswing business wise but has suffered a beating by Mr. Market.

The growth rate has been steady over the past few years and most recently has been at a whopping 30% and change. The PE ratio is nearly half of that and as Peter Lynch would say, of course depending on the sector, that usually indicates a bargain.

ICLR has a ton of cash on hand and no major debts. There's been nothing but positive news about this company or for that matter the sector. I predict this will be back up to mid-$20's within the next two months for a short play and of course it would be a good buy now around or below $18 for the longer term of six to eights months.

Will benefit from pharma outsourcing

In so far as it can be - this is a recession proof stock. CEO, Peter Gray was quoted as saying - "people don't stop buying medicines when there is a recession".

Medical to try and stabilize my bleeding portfolio

Risk reward ratio is fantastic you get biotech exposure with out the risk

TM - drug trial outsourcing

As big pharma trys to reduce costs of geting products to market they will rely more heavily on outsourcing clinical trials.

I agree with most that outsouring is going to continue to be an important aspect of the biotech/pharma cost-cutting methods. ICLR is based in Ireland which gives it some insulation against the slowing US economy; however, I doubt the economy will effect this industry either way.

Good balance sheet, increasing sales, EPS, cash flow last 3 yrs. RoE of 16% is mediocre but better than most competitors. P/S of 2.82. IBD rating of 90/96 for EPS/price strength respectively. 17% inside ownership is a nice addition as well.

I know I'm coming in high, but it looks as if its ready to run some more, its still got more Irish luck...

Look @ it's past in a downword market.

The company has KNOW debt,Just CASH. Why are monet market Mgrs buying in to it?

canslim screener